Figure 6.

Antitumor efficacy of niclosamide in vivo. (A) Nude mice bearing resistant BT474 (BT474-R) cell-derived xenografts were treated with vehicle control, cisplatin (2 mg/kg/week), niclosamide (20 mg/kg/day) or niclosamide (20 mg/kg/day) combined with cisplatin (2 mg/kg/week) from day 14 to day 56. Tumor volume was calculated as length × width2 / 2. (B) Images of Ki67, HER2 and Bcl-2 immunohistochemistry staining of the xenograft tissues. Scale bar, 50 µm. *P<0.05; **P<0.01. Ctrl, control; Cis, cisplatin; Ncm, niclosamide; HER2, human epidermal growth factor receptor 2.